Endocrine News gets the patient and physician perspective on thyroid eye disease. Patients discuss how it has affected their lives and clinicians explain the limited treatment choices. However, new options may be available soon. Christine Gustafson, of Monterey, Calif., swam a mile a day and biked everywhere she went. When she noticed her heart was...
Older Adults with Hypothyroidism Face Elevated Risk of Death
Increased risk does not impact older adults with subclinical hypothyroidism While older adults with hypothyroidism face an elevated risk of death, individuals with subclinical hypothyroidism, a milder form of underactive thyroid, did not face the same risk, according to new research published in The Journal of Clinical Endocrinology & Metabolism. “Our meta-analysis is the first to...
Slightly Elevated TSH Levels Not a Cause for Referral to Pediatric Endocrinologists
Children with thyroid stimulating hormone (TSH) levels slightly above reference range shouldn’t be referred to pediatric endocrinologists unless there is another cause for clinical concern, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Perrin C. White, MD, of the Division of Pediatric Endocrinology at the University of...
New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating...
ATP-binding cassette (ABC) transporters are the major determinants of anaplastic thyroid cancer (ATC) resistance to chemotherapy, and these transporters could be key in tailoring treatments for patients with ATC, according to a paper recently published in Endocrinology. Researchers led by Vahid Haghpanah, MD, MPH, PhD, of the Endocrinology and Metabolism Research at the Tehran University...
In the wake of the recall of hypoparathyroidism drug NATPARA, the drug’s manufacturer, Takeda, is working with the FDA to develop a Special Use Program. The program is intended to support patients previously prescribed NATPARA who are facing life-threatening complications as a result of discontinuation of NATPARA. Through this program, healthcare providers will be able...
Endocrine Society, ASBMR Issue Joint Statement on Natpara Recall
In response to the recent recall of Natpara for the treatment of hypoparathyroidism, the Endocrine Society and the American Society for Bone Mineral Research (ASBMR) have drafted the following guidance for clinicians. The recall of NATPARA®, recombinant human PTH(1-84), in the United States has caused significant concerns and uncertainties for patients with hypoparathyroidism who are...
CEU PREVIEW: Graves’ Anatomy: Transatlantic Differences in Treating Graves’ Hyperthyroidism
Disagreements abound in treating Graves’ hyperthyroidism from the U.S. to Europe as different treatment protocols take precedence. In both Seattle and Miami, “Diagnosis and Management of Graves’ Hyperthyroidism” will demonstrate these conflicting practices and the progress that has been achieved. Graves’ disease – the most common cause of hyperthyroidism – affects between 1% and 1.5%...Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.
